To investigate whether hFTN-RFP can elicit the RFP-specific anti-tumor immune responses, the strength of CD8+ T cell response was assessed in the C57BL/6 mice that were subcutaneously vaccinated with hFTN-RFP (10 μM), RFP (10 μM), hFTN (10 μM), and PBS, three times with 1-week interval. This evidence concerns the gene CD8A and neoplasm.